home / stock / gnmx / gnmx quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.1659 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:27:58 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $0.1659 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $0.1825 | $0.1659 | $0.1836 | $0.15 | 2,672,397 | 02-03-2020 |
$ | $0.19 | $0.185 | $0.193 | $0.185 | 1,009,042 | 01-31-2020 |
$ | $0.1985 | $0.1879 | $0.20 | $0.1855 | 746,670 | 01-30-2020 |
$ | $0.1909 | $0.1955 | $0.20 | $0.188 | 927,519 | 01-29-2020 |
$ | $0.193 | $0.1886 | $0.1999 | $0.188 | 699,159 | 01-28-2020 |
$ | $0.195 | $0.188 | $0.20 | $0.1858 | 1,064,801 | 01-27-2020 |
$ | $0.201 | $0.1998 | $0.21 | $0.19 | 1,380,608 | 01-24-2020 |
$ | $0.2071 | $0.2082 | $0.23 | $0.205 | 2,789,151 | 01-23-2020 |
$ | $0.20 | $0.2197 | $0.29 | $0.196 | 12,803,861 | 01-22-2020 |
$ | $0.1914 | $0.1927 | $0.1958 | $0.1833 | 1,790,021 | 01-21-2020 |
$ | $0.195 | $0.1825 | $0.199 | $0.1815 | 1,434,305 | 01-20-2020 |
$ | $0.195 | $0.1825 | $0.199 | $0.1815 | 1,408,291 | 01-17-2020 |
$ | $0.1806 | $0.1925 | $0.20 | $0.1801 | 1,871,788 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Aevi Genomic Medicine Inc. Company Name:
GNMX Stock Symbol:
NASDAQ Market:
Aevi Genomic Medicine Inc. Website:
-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceu...
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company&...
-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explored for Neurological Assets and Millipred ...